Cite
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.
MLA
Wang, Yang, et al. “Evaluation of Efficacy and Toxicity of Nivolumab Combined with or without Docetaxel in Patients with Advanced NSCLC.” Cancer Immunology, Immunotherapy, vol. 71, no. 2, Feb. 2022, pp. 267–76. EBSCOhost, https://doi.org/10.1007/s00262-021-02964-x.
APA
Wang, Y., Nie, J., Dai, L., Hu, W., Zhang, J., Chen, X., Ma, X., Tian, G., Han, J., Han, S., Wu, D., Long, J., Zhang, Z., & Fang, J. (2022). Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. Cancer Immunology, Immunotherapy, 71(2), 267–276. https://doi.org/10.1007/s00262-021-02964-x
Chicago
Wang, Yang, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, et al. 2022. “Evaluation of Efficacy and Toxicity of Nivolumab Combined with or without Docetaxel in Patients with Advanced NSCLC.” Cancer Immunology, Immunotherapy 71 (2): 267–76. doi:10.1007/s00262-021-02964-x.